<DOC>
	<DOCNO>NCT02013817</DOCNO>
	<brief_summary>This study evaluate efficacy safety intense combination treatment include MabThera/Rituxan ( rituximab ) , follow MabThera/Rituxan maintenance therapy patient B-cell CLL naive chemotherapy . The anticipated time study treatment 2.5 year .</brief_summary>
	<brief_title>CHAIROS Study A Study MabThera/Rituxan ( Rituximab ) Maintenance Therapy Patients With B-Cell Chronic Lymphocytic Leukemia ( CLL ) Naive Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Bcell CLL No previous chemotherapy , radiotherapy , immunotherapy Reduced organ function , bone marrow dysfunction due CLL Patients history malignancy within 2 year prior study entry , except adequately treated cancer situ cervix , basal squamous cell skin cancer Patients history severe cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>